Drug Trial Radar · NCT00773513
A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)
Last checked: Nov 19, 2026Latest source record: Aug 20, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,825
Actual
Start
Dec 12, 2008
Primary completion
Jul 27, 2017
Study completion Jul 27, 2017
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Oct 16, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This 2 arm safety study will compare the outcome with respect to a composite endpoint of all-cause mortality and non-fatal cardiovascular events (myocardial infarction, stroke) in CKD participants either on dialysis or not receiving renal replacement therapy under treatment with methoxy polyethylene glycol-epoetin beta or reference ESAs. Participants will be randomized to receive intravenous (iv) or subcutaneous (sc) methoxy polyethylene glycol-epoetin beta at the following doses: for participants not already receiving ESA treatment, methoxy polyethylene glycol-epoetin beta will be administered at a starting dose of 0.6 micrograms per kilograms every 2 weeks (mcg/kg/2wks) iv or sc; for participants receiving maintenance ESA treatment, iv or sc methoxy polyethylene glycol-epoetin beta will be administered at an initial monthly dose of 120, 200 or 360 micrograms (mcg) depending on the weekly dose of ESA received prior to first methoxy polyethylene glycol-epoetin beta administration. Participants randomized to reference ESA treatment will receive iv or sc ESAs in accordance with their prescribed dosing information.
Conditions
- Chronic Renal Anemia
Interventions
Darbepoetin AlfaDrug
Darbepoetin alfa will be administered as per approved label.
Epoetin AlfaDrug
Epoetin alfa will be administered as per approved label.
Epoetin BetaDrug
Epoetin beta will be administered as per approved label.
methoxy polyethylene glycol-epoetin betaDrug
Participants who are currently not being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta administered at a starting dose of 0.6 mcg/kg body weight once every 2 weeks. Participants who are currently being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta at a dose of 120, 200 or 360 mcg once monthly (based on ESA dose administered in Week -1)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Composite of All-Cause Mortality and Non-Fatal Cardiovascular Events (Myocardial Infarction, Stroke) Defined as Time Between First Dose of Study Medication and Date of Death or Non-Fatal Cardiovascular Events, Whichever Occurred FirstTime frame: Baseline up to approximately 8.5 years
Locations
196 sites in 27 countries. Site status is shown where the registry gives one.
Fresenius Medical Care Martinez
Buenos Aires, Argentina
Fresenius Medical Care Morón
Buenos Aires, Argentina
Fresenius Medical Care San Martin
Buenos Aires, Argentina
Fresenuis Medical Care Mansilla
CABA, Argentina
Gosford Hospital; Renal
Gosford, New South Wales, Australia
Renal Research Dr Simon Roger
Gosford, New South Wales, Australia
Cairns Hospital; Renal Services
Cairns, Queensland, Australia
Gold Coast Hospital Department of Pharmacology & Therapeutics
Southport, Queensland, Australia
ROYAL ADELAIDE HOSPITAL; Renal Clinical Trials, CNARTS
Adelaide, South Australia, Australia
Launceston General Hospital; Diabetes and Renal Research Unit
Launceston, Tasmania, Australia
Monash Medical Centre; Renal Transplant Unit
Clayton, Victoria, Australia
Royal Perth Hospital; Nephrology
Perth, Western Australia, Australia
UZ Brussel
Brussels, Belgium
UZ Gent
Ghent, Belgium
Jessa Zkh (Campus Virga Jesse)
Hasselt, Belgium
UZ Leuven Gasthuisberg
Leuven, Belgium
AZ Delta (Campus Wilgenstraat)
Roeselare, Belgium
Centro Mineiro de Pesquisa - CMIP
Juiz de Fora, Minas Gerais, Brazil
PUCPR
Curitiba, Paraná, Brazil
Hospital Univ. Pedro Ernesto - Hupe; Nefrologia
Rio de Janeiro, Rio de Janeiro, Brazil
Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Sao Lucas - PUCRS
Porto Alegre, Rio Grande do Sul, Brazil
Beneficencia Portuguesa de Sao Paulo
São Paulo, São Paulo, Brazil
Universidade Federal de Sao Paulo - UNIFESP
São Paulo, São Paulo, Brazil
Clinica de Medicina Interna e Nefrologia (CMIN)
São Paulo, São Paulo, Brazil
Hospital das Clinicas - FMUSP; Nefrologia
São Paulo, São Paulo, Brazil
Instituto de Hemodialise Sorocaba
Sorocaba, São Paulo, Brazil
General Hospital Karlovac; Dept of Haemodialysis
Karlovac, Croatia
Clinical Hospital Osijek; Dept of Haemodialysis
Osijek, Croatia
Clinical Hospital Center Rijeka; Dialysis
Rijeka, Croatia
General Hospital Josip Bencevic; Department of Haemodialysis
Slavonski Brod, Croatia
Clinical Hospital Split; Dialysis
Split, Croatia
General Hospital Zadar; Dialysis
Zadar, Croatia
Klinicki Bolnicki Centar Zagreb; Dialysis
Zagreb, Croatia
Fakultni Nemocnice Kralovske Vinohrady (FNKV); Interni Hematologicka Klinika
Hradec Králové, Czechia
Faculty Hospital; Dialysis Unit
Ostrava, Czechia
Institut Klinicke A Experimentalni Mediciny Klinika Nefrologie
Prague, Czechia
Nemocnice Strahov; Interni Oddeleni-Strahov
Prague, Czechia
Centre Hospitalier; Hemodialyse
Annonay, France
Hopital Pellegrin; Departement Nephrologie
Bordeaux, France
Showing 40 of 196 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.